Stem cell transplantation for primary immunodeficiencies.

Area of Science:

• Pediatric Hematology
• Immunology
• Transplantation Medicine

Background:

• Severe primary immunodeficiencies (PIDs) are rare genetic disorders affecting the immune system.
• Bone marrow transplantation (BMT) is a curative treatment for many children with PIDs, with recent advances improving success rates.
• Matched unrelated donors (MUDs) have expanded BMT accessibility.

Purpose of the Study:

• To review current indications for BMT in pediatric PIDs.
• To discuss the role of MUDs in improving BMT outcomes.
• To explore the evolving landscape of PID treatment, including gene therapy, and its impact on BMT indications.

Main Methods:

• Literature review of BMT for primary immunodeficiencies.
• Analysis of outcomes associated with MUDs.
• Discussion of emerging alternative therapies such as gene therapy.

Main Results:

• BMT is curative in approximately 75% of children with severe PIDs.
• The use of MUDs has increased the likelihood of successful BMT.
• Survival rates for infants undergoing BMT with a MUD exceed 80%.

Conclusions:

• BMT remains a cornerstone for severe PIDs, especially with MUD availability.
• Indications for BMT in PIDs with less severe phenotypes or quality-of-life impacts require further definition.
• The advent of gene therapy presents a potential alternative or complementary treatment for certain PIDs.